Thyroid hormone analogs for the treatment of dyslipidemia: past, present, and future

References

• Kern DM, Mellstrom C, Hunt PR, et al. Long-term cardiovascular risk and costs for myocardial infarction survivors in a US commercially insured population. Curr Med Res Opin 2016;32:703-11
   PubMed Web of Science ®Google Scholar
• Vedanthan R, Bansilal S, Soto AV, et al. Family-based approaches to cardiovascular health promotion. J Am Coll Cardiol 2016;67:1725-37
   PubMed Web of Science ®Google Scholar
• Scuteri A, Morrell CH, Orru M, et al. Longitudinal perspective on the conundrum of central arterial stiffness, blood pressure, and aging. Hypertension 2014;64:1219-27
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation 2015;131:e29-322
   PubMed Web of Science ®Google Scholar
• Wierzbicki AS, Mikhailidis DP, Wray R, et al. Statin-fibrate combination: therapy for hyperlipidemia: a review. Curr Med Res Opin 2003;19:155-68
   PubMed Web of Science ®Google Scholar
• Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007;115:450-8
   PubMed Web of Science ®Google Scholar
• Bennet A, Di Angelantonio E, Erqou S, et al. Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. Arch Intern Med 2008;168:598-608
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009;361:2113-22
   PubMed Web of Science ®Google Scholar
• Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1500-9
   PubMed Web of Science ®Google Scholar
• Delitala AP, Pilia MG, Ferreli L, et al. Prevalence of unknown thyroid disorders in a Sardinian cohort. Eur J Endocrinol 2014;171:143-9
   PubMed Web of Science ®Google Scholar
• Delitala AP, Fanciulli G, Pes GM, et al. Thyroid hormones, metabolic syndrome and its components. Endocr Metab Immune Disord Drug Targets 2017. doi: 10.2174/1871530317666170320105221
   PubMed Web of Science ®Google Scholar
• Christ-Crain M, Meier C, Guglielmetti M, et al. Elevated C-reactive protein and homocysteine values: cardiovascular risk factors in hypothyroidism? A cross-sectional and a double-blind, placebo-controlled trial. Atherosclerosis 2003;166:379-86
   PubMed Web of Science ®Google Scholar
• Chadarevian R, Bruckert E, Leenhardt L, et al. Components of the fibrinolytic system are differently altered in moderate and severe hypothyroidism. J Clin Endocrinol Metab 2001;86:732-7
   PubMed Web of Science ®Google Scholar
• Delitala AP, Filigheddu F, Orru M, et al. No evidence of association between subclinical thyroid disorders and common carotid intima medial thickness or atherosclerotic plaque. Nutr Metab Cardiovasc Dis 2015;25:1104-10
   PubMed Web of Science ®Google Scholar
• Delitala AP, Orru M, Filigheddu F, et al. Serum free thyroxine levels are positively associated with arterial stiffness in the SardiNIA study. Clin Endocrinol (Oxf) 2015;82:592-7
   PubMed Web of Science ®Google Scholar
• Shin DJ, Osborne TF. Thyroid hormone regulation and cholesterol metabolism are connected through Sterol Regulatory Element-Binding Protein-2 (SREBP-2). J Biol Chem 2003;278:34114-8
   PubMed Web of Science ®Google Scholar
• Pearce EN. Hypothyroidism and dyslipidemia: modern concepts and approaches. Curr Cardiol Rep 2004;6:451-6
   PubMedGoogle Scholar
• Duntas LH, Brenta G. The effect of thyroid disorders on lipid levels and metabolism. Med Clin North Am 2012;96:269-81
   PubMed Web of Science ®Google Scholar
• Delitala AP, Fanciulli G, Maioli M, et al. Subclinical hypothyroidism, lipid metabolism and cardiovascular disease. Eur J Intern Med 2017;38:17-24
   PubMed Web of Science ®Google Scholar
• Delitala AP, Steri M, Pilia MG, et al. Menopause modulates the association between thyrotropin levels and lipid parameters: The SardiNIA study. Maturitas 2016;92:30-4
   PubMed Web of Science ®Google Scholar
• Grover GJ, Egan DM, Sleph PG, et al. Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: selective actions relative to 3,5,3'-triiodo-L-thyronine. Endocrinology 2004;145:1656-61
   PubMed Web of Science ®Google Scholar
• Grover GJ, Mellstrom K, Ye L, et al. Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability. Proc Natl Acad Sci USA 2003;100:10067-72
   PubMed Web of Science ®Google Scholar
• Klein I, Danzi S. Thyroid disease and the heart. Circulation 2007;116:1725-35
   PubMed Web of Science ®Google Scholar
• Gogakos AI, Duncan Bassett JH, Williams GR. Thyroid and bone. Arch Biochem Biophys 2010;503:129-36
   PubMed Web of Science ®Google Scholar
• Baxter JD, Webb P. Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes. Nat Rev Drug Discov 2009;8:308-20
   PubMed Web of Science ®Google Scholar
• Webb P. Selective activators of thyroid hormone receptors. Expert Opin Investig Drugs 2004;13:489-500
   PubMed Web of Science ®Google Scholar
• Moreno M, de Lange P, Lombardi A, et al. Metabolic effects of thyroid hormone derivatives. Thyroid 2008;18:239-53
   PubMed Web of Science ®Google Scholar
• Berkenstam A, Kristensen J, Mellstrom K, et al. The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. Proc Natl Acad Sci USA 2008;105:663-7
   PubMed Web of Science ®Google Scholar
• Zhang J, Lazar MA. The mechanism of action of thyroid hormones. Annu Rev Physiol 2000;62:439-66
   PubMed Web of Science ®Google Scholar
• Lazar MA. Thyroid hormone receptors: multiple forms, multiple possibilities. Endocr Rev 1993;14:184-93
   PubMed Web of Science ®Google Scholar
• Ikeda M, Rhee M, Chin WW. Thyroid hormone receptor monomer, homodimer, and heterodimer (with retinoid-X receptor) contact different nucleotide sequences in thyroid hormone response elements. Endocrinology 1994;135:1628-38
   PubMed Web of Science ®Google Scholar
• Katz D, Lazar MA. Dominant negative activity of an endogenous thyroid hormone receptor variant (alpha 2) is due to competition for binding sites on target genes. J Biol Chem 1993;268:20904-10
   PubMed Web of Science ®Google Scholar
• Williams GR. Cloning and characterization of two novel thyroid hormone receptor beta isoforms. Mol Cell Biol 2000;20:8329-42
   PubMed Web of Science ®Google Scholar
• Brenta G, Danzi S, Klein I. Potential therapeutic applications of thyroid hormone analogs. Nat Clin Pract Endocrinol Metab 2007;3:632-40
   PubMedGoogle Scholar
• Yen PM. Physiological and molecular basis of thyroid hormone action. Physiol Rev 2001;81:1097-142
   PubMed Web of Science ®Google Scholar
• Weinberger C, Thompson CC, Ong ES, et al. The c-erb-A gene encodes a thyroid hormone receptor. Nature 1986;324:641-6
   PubMed Web of Science ®Google Scholar
• Apriletti JW, Ribeiro RC, Wagner RL, et al. Molecular and structural biology of thyroid hormone receptors. Clin Exp Pharmacol Physiol Suppl 1998;25:S2-S11
   PubMedGoogle Scholar
• Zhu X, Cheng SY. New insights into regulation of lipid metabolism by thyroid hormone. Curr Opin Endocrinol Diabetes Obes 2010;17:408-13
   PubMed Web of Science ®Google Scholar
• Angelin B, Rudling M. Lipid lowering with thyroid hormone and thyromimetics. Curr Opin Lipidol 2010;21:499-506
   PubMed Web of Science ®Google Scholar
• Refetoff S, Weiss RE, Usala SJ. The syndromes of resistance to thyroid hormone. Endocr Rev 1993;14:348-99
   PubMed Web of Science ®Google Scholar
• Hiroi Y, Kim HH, Ying H, et al. Rapid nongenomic actions of thyroid hormone. Proc Natl Acad Sci USA 2006;103:14104-9
   PubMed Web of Science ®Google Scholar
• Liang H, Juge-Aubry CE, O’Connell M, et al. Organ-specific effects of 3,5,3'-triiodothyroacetic acid in rats. Eur J Endocrinol 1997;137:537-44
   PubMed Web of Science ®Google Scholar
• Lameloise N, Siegrist-Kaiser C, O’Connell M, et al. Differences between the effects of thyroxine and tetraiodothyroacetic acid on TSH suppression and cardiac hypertrophy. Eur J Endocrinol 2001;144:145-54
   PubMed Web of Science ®Google Scholar
• Mason RLH, Hunt M, Hurxthal L. Blood cholesterol values in hyperthyroidism and hypothyroidism-their significance. N Engl J Med 1930;203:1273-8
   Google Scholar
• Galioni EF, Gofman JW, Guzvich P, et al. Long-term effect of dried thyroid on serum-lipoprotein and serum-cholesterol levels. Lancet 1957;272:120-3
   PubMed Web of Science ®Google Scholar
• The coronary drug project. Findings leading to further modifications of its protocol with respect to dextrothyroxine. The coronary drug project research group. JAMA 1972;220:996-1008
   PubMed Web of Science ®Google Scholar
• Redgrave TG, Elsegood CL, Mamo JC, et al. Effects of hypothyroidism on the metabolism of lipid emulsion models of triacylglycerol-rich lipoproteins in rats. Biochem J 1991;273(Pt 2):375-81
   PubMed Web of Science ®Google Scholar
• Barlow JW, Raggatt LE, Lim CF, et al. The thyroid hormone analogue SKF-94901 and iodothyronine binding sites in mammalian tissues: differences in cytoplasmic binding between liver and heart. Acta Endocrinol (Copenh) 1991;124:37-44
   PubMedGoogle Scholar
• Goldman S, McCarren M, Morkin E, et al. DITPA (3,5-diiodothyropropionic acid), a thyroid hormone analog to treat heart failure: phase II trial veterans affairs cooperative study. Circulation 2009;119:3093-100
   PubMed Web of Science ®Google Scholar
• Ladenson PW, McCarren M, Morkin E, et al. Effects of the thyromimetic agent diiodothyropropionic acid on body weight, body mass index, and serum lipoproteins: a pilot prospective, randomized, controlled study. J Clin Endocrinol Metab 2010;95:1349-54
   PubMed Web of Science ®Google Scholar
• Borngraeber S, Budny MJ, Chiellini G, et al. Ligand selectivity by seeking hydrophobicity in thyroid hormone receptor. Proc Natl Acad Sci USA 2003;100:15358-63
   PubMed Web of Science ®Google Scholar
• Trost SU, Swanson E, Gloss B, et al. The thyroid hormone receptor-beta-selective agonist GC-1 differentially affects plasma lipids and cardiac activity. Endocrinology 2000;141:3057-64
   PubMed Web of Science ®Google Scholar
• Villicev CM, Freitas FR, Aoki MS, et al. Thyroid hormone receptor beta-specific agonist GC-1 increases energy expenditure and prevents fat-mass accumulation in rats. J Endocrinol 2007;193:21-9
   PubMed Web of Science ®Google Scholar
• Grijota-Martinez C, Samarut E, Scanlan TS, et al. In vivo activity of the thyroid hormone receptor beta- and alpha-selective agonists GC-24 and CO23 on rat liver, heart, and brain. Endocrinology 2011;152:1136-42
   PubMed Web of Science ®Google Scholar
• Lanni A, Moreno M, Lombardi A, et al. 3,5-diiodo-L-thyronine powerfully reduces adiposity in rats by increasing the burning of fats. FASEB J 2005;19:1552-4
   PubMed Web of Science ®Google Scholar
• de Lange P, Cioffi F, Senese R, et al. Nonthyrotoxic prevention of diet-induced insulin resistance by 3,5-diiodo-L-thyronine in rats. Diabetes 2011;60:2730-9
   PubMed Web of Science ®Google Scholar
• Antonelli A, Fallahi P, Ferrari SM, et al. 3,5-diiodo-L-thyronine increases resting metabolic rate and reduces body weight without undesirable side effects. J Biol Regul Homeost Agents 2011;25:655-60
   PubMed Web of Science ®Google Scholar
• Grover GJ, Mellstrom K, Malm J. Development of the thyroid hormone receptor beta-subtype agonist KB-141: a strategy for body weight reduction and lipid lowering with minimal cardiac side effects. Cardiovasc Drug Rev 2005;23:133-48
   PubMed Web of Science ®Google Scholar
• Ladenson PW, Kristensen JD, Ridgway EC, et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med 2010;362:906-16
   PubMed Web of Science ®Google Scholar
• Day R, Gebhard RL, Schwartz HL, et al. Time course of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and messenger ribonucleic acid, biliary lipid secretion, and hepatic cholesterol content in methimazole-treated hypothyroid and hypophysectomized rats after triiodothyronine administration: possible linkage of cholesterol synthesis to biliary secretion. Endocrinology 1989;125:459-68
   PubMed Web of Science ®Google Scholar
• Gullberg H, Rudling M, Salto C, et al. Requirement for thyroid hormone receptor beta in T3 regulation of cholesterol metabolism in mice. Mol Endocrinol 2002;16:1767-77
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Yamada M, Matsumoto S, et al. Mouse sterol response element binding protein-1c gene expression is negatively regulated by thyroid hormone. Endocrinology 2006;147:4292-302
   PubMed Web of Science ®Google Scholar
• Galman C, Bonde Y, Matasconi M, et al. Dramatically increased intestinal absorption of cholesterol following hypophysectomy is normalized by thyroid hormone. Gastroenterology 2008;134:1127-36
   PubMed Web of Science ®Google Scholar
• Bonde Y, Breuer O, Lutjohann D, et al. Thyroid hormone reduces PCSK9 and stimulates bile acid synthesis in humans. J Lipid Res 2014;55:2408-15
   PubMed Web of Science ®Google Scholar
• Kelly MJ, Pietranico-Cole S, Larigan JD, et al. Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dio xo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a highly selective thyroid hormone receptor beta agonist in clinical trials for the treatment of dyslipidemia. J Med Chem 2014;57:3912-23
   PubMed Web of Science ®Google Scholar
• Boyer SH, Jiang H, Jacintho JD, et al. Synthesis and biological evaluation of a series of liver-selective phosphonic acid thyroid hormone receptor agonists and their prodrugs. J Med Chem 2008;51:7075-93
   PubMed Web of Science ®Google Scholar
• Fujitaki JM, Cable EE, Ito BR, et al. Preclinical pharmacokinetics of a HepDirect prodrug of a novel phosphonate-containing thyroid hormone receptor agonist. Drug Metab Dispos 2008;36:2393-403
   PubMed Web of Science ®Google Scholar
• Erion MD, Cable EE, Ito BR, et al. Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index. Proc Natl Acad Sci USA 2007;104:15490-5
   PubMed Web of Science ®Google Scholar
• Ito BR, Zhang BH, Cable EE, et al. Thyroid hormone beta receptor activation has additive cholesterol lowering activity in combination with atorvastatin in rabbits, dogs and monkeys. Br J Pharmacol 2009;156:454-65
   PubMed Web of Science ®Google Scholar
• Takahashi N, Maeda K, Asano Y, et al. Synthesis and pharmacological characterization of 1-benzyl-4-aminoindole-based thyroid hormone receptor beta agonists. Bioorg Med Chem 2014;22:488-98
   PubMed Web of Science ®Google Scholar
• Takahashi N, Asano Y, Maeda K, et al. In vivo evaluation of 1-benzyl-4-aminoindole-based thyroid hormone receptor beta agonists: importance of liver selectivity in drug discovery. Biol Pharm Bull 2014;37:1103-8
   PubMed Web of Science ®Google Scholar
• Johansson L, Rudling M, Scanlan TS, et al. Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice. Proc Natl Acad Sci USA 2005;102:10297-302
   PubMed Web of Science ®Google Scholar
• Gloss B, Trost S, Bluhm W, et al. Cardiac ion channel expression and contractile function in mice with deletion of thyroid hormone receptor alpha or beta. Endocrinology 2001;142:544-50
   PubMed Web of Science ®Google Scholar
• Sjouke B, Langslet G, Ceska R, et al. Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study. Lancet Diabetes Endocrinol 2014;2:455-63
   PubMed Web of Science ®Google Scholar
• Angelin B, Kristensen JD, Eriksson M, et al. Reductions in serum levels of LDL cholesterol, apolipoprotein B, triglycerides and lipoprotein(a) in hypercholesterolaemic patients treated with the liver-selective thyroid hormone receptor agonist eprotirome. J Intern Med 2015;277:331-42
   PubMed Web of Science ®Google Scholar
• Taub R, Chiang E, Chabot-Blanchet M, et al. Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-beta agonist. Atherosclerosis 2013;230:373-80
   PubMed Web of Science ®Google Scholar
• Meruvu S, Ayers SD, Winnier G, et al. Thyroid hormone analogues: where do we stand in 2013? Thyroid 2013;23:1333-44
   PubMed Web of Science ®Google Scholar
• Doycheva I, Watt KD, Alkhouri N. Nonalcoholic fatty liver disease in adolescents and young adults: the next frontier in the epidemic. Hepatology 2017;65:2100-109
   PubMed Web of Science ®Google Scholar
• Martagon AJ, Lin JZ, Cimini SL, et al. The amelioration of hepatic steatosis by thyroid hormone receptor agonists is insufficient to restore insulin sensitivity in ob/ob mice. PLoS One 2015;10:e0122987
   PubMed Web of Science ®Google Scholar
• Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid 2012;22:1200-35
   PubMed Web of Science ®Google Scholar
• Bryzgalova G, Effendic S, Khan A, et al. Anti-obesity, anti-diabetic, and lipid lowering effects of the thyroid receptor beta subtype selective agonist KB-141. J Steroid Biochem Mol Biol 2008;111:262-7
   PubMed Web of Science ®Google Scholar